USAMRIID

What USAMRIID does

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), founded in 1969 and headquartered at Fort Detrick, Maryland, is the Department of Defense's lead laboratory for medical biological defense research. It operates the only DoD Biosafety Level 4 maximum containment facility, alongside BSL-3 laboratories, enabling study of the most hazardous viruses and emerging infectious disease threats. The institute's primary customers are the U.S. military Warfighter population, DoD medical commands, and allied public health agencies; secondary audiences include civilian healthcare professionals and partner-nation laboratories in Africa, Asia, and the Americas. USAMRIID's mission is to deliver leading-edge medical capabilities, including vaccines, therapeutics, diagnostics, and training, that deter and defend against current and emerging biological threat agents.

USAMRIID's core technology base centers on BSL-3 and BSL-4 containment infrastructure with positive-pressure encapsulating suits, controlled aerosol exposure systems for animal-model studies, and proprietary antibody discovery workflows that screen survivor blood samples for protective monoclonals. Documented proprietary outputs include the ultra-potent hantavirus antibody (developed with Albert Einstein College of Medicine, effective against multiple strains in animal models), the MAb-9D5 antibody targeting the CCHFV nucleocapsid protein, MBP134 (the first experimental treatment protecting animal models against Sudan Ebola Virus and two other Ebola species), and EVUSHELD (which received FDA emergency use authorization for COVID-19 protection). The institute also maintains a 3D bioprinted vascular liver tissue model, nonhuman primate Ebola virus persistence models, and the Biodefense Reference Material Repository. Research is published in top-tier journals including Science Translational Medicine.

USAMRIID is funded through federal Department of Defense appropriations rather than commercial revenue and operates as a subordinate laboratory of the U.S. Army Medical Research and Development Command (USAMRDC) under the Defense Health Agency. Three in-resident training courses (MCBC, FCBC, HM-CBRNE) and the JKO distance-learning course are delivered at no tuition to military and civilian healthcare professionals via the Army Training Requirements and Resources System. The institute runs a technology transfer and patent licensing program to commercialize research outputs and conducts overseas training in partner nations under the Global Emerging Infection Surveillance program. Marketing channels include the official .mil website, Facebook, Instagram, LinkedIn, the Military Health System Research Symposium, the Maryland STEM Festival, and the One Health Podcast.

Name

USAMRIID

Legal name

U.S. Army Medical Research Institute of Infectious Diseases

Website

https://usamriid.health.mil

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The U.S. Army Medical Research Institute of Infectious Diseases is the Department of Defense's lead laboratory for medical biological defense research and the only DoD facility with Biosafety Level 4 containment capability. It develops vaccines, drugs, and diagnostics against biological threats and delivers no-cost training to military and civilian healthcare professionals.

Ownership category

akta.pro rank

Product category

Biodefense Research

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Defense R&D, Test, Evaluation & Innovation (BPAIAHAC)

akta.pro secondary industries

Biothreat/Biocontainment & Select Agent Public Health Laboratories (HLAJAIAL), Animal Health Emergency Preparedness & Outbreak Response (HLAMAJAD)

Keywords

• Biodefense research
• Medical countermeasures
• Infectious disease research
• Biosafety Level 4
• CBRNE training

Headquarters

HQ city

Frederick

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Others

Revenue model

1. Federal Government Appropriations: As a U.S. Army research institute under the Department of Defense, USAMRIID is funded through federal government appropriations and defense budgets. Research leads to vaccines, drugs, diagnostics, and training programs that protect both Warfighters and civilians.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels11 records

Core offering

USAMRIID is the U.S. Army Medical Research Institute of Infectious Diseases and the Department of Defense's lead laboratory for medical biological defense research. It conducts research in Biosafety Level 3 and the only DoD Biosafety Level 4 maximum-containment laboratories to develop vaccines, therapeutics, diagnostics, and training programs that protect Warfighters and civilians against current and emerging biological threats. It also delivers tuition-free in-resident CBRNE training courses and provides reach-back Subject Matter Expert consultation and Laboratory Response Network capabilities.

Product overview

USAMRIID offers a suite of biodefense products and services centered on research, training, and educational resources for biological threat defense. The core offerings include the USAMRIID Biodefense Tool mobile application for field identification of biological agents, three in-resident training programs (MCBC, FCBC, and HM-CBRNE) providing hands-on education for military and civilian healthcare professionals, and published reference materials including the Blue Book and Quick Bio-Agents Guide. Research conducted at USAMRIID leads to vaccines, drugs, diagnostics, and training programs that protect both Warfighters and civilians against current and emerging biological threat agents.

Differentiator

Problem solved

Functional benefit

Products and services

• USAMRIID Biodefense Tool Mobile Application
• Medical Management of Chemical and Biological Casualties Course (MCBC)
• Field Management of Chemical & Biological Casualties (FCBC)
• Hospital Management of Chemical, Biological, Radiological, Nuclear & Explosive Incidents (HM-CBRNE)
• Medical Management of Biological Casualties Handbook (Blue Book)
• Quick Bio-Agents Guide (Pocket Reference Guide to Biological Select Agents & Toxins)
• JKO Medical Management of Biological Casualties Course
• Textbook of Military Medicine - Medical Aspects of Biological Warfare

Quantifiable outcome

• First monoclonal antibody to demonstrate cross-protective efficacy against both Old and New World hantaviruses
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Walter Reed Army Institute of Research (WRAIR): Sister U.S. Army medical research institute under USAMRDC; conducts infectious disease and military medicine R&D and shares the same parent command and research-mission posture as USAMRIID.
• MRIGlobal: Independent nonprofit research organization operating BSL-3/BSL-4 facilities and providing infectious-disease and CBRN research services to federal clients, including DoD.
• U.S. Army Medical Research Institute of Chemical Defense (USAMRICD): Co-located DoD medical defense institute focused on chemical casualties; partners with USAMRIID on joint CBRNE training courses (FCBC, HM-CBRNE) at Aberdeen Proving Ground.
• United States Army Medical Materiel Development Activity (USAMMDA): U.S. Army activity that develops and fields FDA-regulated medical products; downstream counterpart to USAMRIID's discovery-stage R&D within the same USAMRDC command structure.

Emerging players

• Battelle Memorial Institute: Nonprofit applied R&D provider with extensive government and defense contracts in life sciences, biodefense, and CBRN — comparable as a federal-contracting research-services peer.
• Lovelace Biomedical & Environmental Research Institute: Private nonprofit with BSL-3 and BSL-4 capabilities, performing infectious-disease and aerosol-exposure animal-model research for government and biodefense clients.

Broad incumbents

• National Institute of Allergy and Infectious Diseases (NIAID): Larger U.S. government funder and performer of infectious-disease R&D; the primary civilian counterpart to USAMRIID for BSL-4 pathogen research, vaccine development, and outbreak response.
• Centers for Disease Control and Prevention (CDC): Federal public health agency with overlapping laboratory and outbreak-response mandates; co-developed the FDA-approved anthrax test with USAMRIID and partners on select-agent diagnostics.
• Biomedical Advanced Research and Development Authority (BARDA): HHS office that funds late-stage development of medical countermeasures; a key downstream partner for USAMRIID-discovered vaccines and therapeutics that move toward FDA approval.
• Defense Advanced Research Projects Agency (DARPA): DoD R&D agency funding high-risk biological and health research; overlapping funder/partner for advanced biodefense technology programs relevant to USAMRIID's mission.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/usamriid
• Instagraminstagram.com/usamrdc
• Xx.com/OUSAMRIID

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about USAMRIID